Commissioned Research
Top 10 Best Health Economics Services of 2026

GITNUXSOFTWARE ADVICE

Economics

Top 10 Best Health Economics Services of 2026

Compare health economics services with clear tradeoffs and fit for healthcare teams, using market research examples from Milliman and peers.

19 min readUpdated Editorially scoped research
How we ranked these tools
01Editorial Scope

Vendors set the topic, but our editors set the inclusion criteria and the evaluation framework before research starts.

02Source Research

Agents extract product evidence with provenance, then collect written reviews and transcribe video reviews and podcasts.

Read our full methodology →

Framework: Features 40% · Ease 30% · Value 30%

Gitnux may earn a commission through links on this page — this does not influence rankings. Editorial policy

Health economics service providers turn clinical evidence into payer-grade value evidence using model design, outcomes analytics, and pricing and market access support. This comparison helps technical buyers weigh delivery fit such as data and analytics depth, integration and automation for evidence production, and governance like audit-ready documentation and configurable workflows.

Milliman is the best choice for payer and sponsor teams needing rigorous, consultant-built economic models because it gives end-to-end control of assumptions from evidence inputs through decision-ready framing, while L.E.K. Consulting fits when reimbursement stakeholders need repeatable, traceable scenario reruns.

Editor’s top 3 picks

Three quick recommendations before you dive into the full comparison below — each one leads on a different dimension.

Editor pick
1

Milliman

End-to-end control of economic model assumptions from evidence inputs through results framing for decision committees.

Best for: Fits when payer and sponsor teams need rigorous, consultant-built economic models with decision-ready documentation.

2

L.E.K. Consulting

Editor pick

End-to-end economic modeling and evidence-to-outputs traceability that supports repeatable scenario reruns for policy decisions.

Best for: Fits when reimbursement and payer stakeholders need defensible economic modeling, sensitivity logic, and traceable assumptions.

3

Simon-Kucher & Partners

Editor pick

Decision narrative integration that connects model assumptions and scenario results to commercial and HTA-facing positions.

Best for: Fits when teams need decision-ready health economics tied to pricing and reimbursement negotiation.

Comparison Table

1
MillimanBest overall
specialist
9.0/10
Overall
2
enterprise_vendor
8.8/10
Overall
3
enterprise_vendor
8.6/10
Overall
4
enterprise_vendor
8.3/10
Overall
5
enterprise_vendor
8.2/10
Overall
6
7.7/10
Overall
7
7.5/10
Overall
8
7.0/10
Overall
9
6.8/10
Overall
10
specialist
6.7/10
Overall
#1

Milliman

specialist

Actuarial and healthcare consulting firm offering health economics and policy analysis.

9.0/10
Overall
Features9.0/10
Ease of Use9.0/10
Value9.0/10
Standout feature

End-to-end control of economic model assumptions from evidence inputs through results framing for decision committees.

Milliman typically delivers custom economic models built around specified decision contexts, such as reimbursement strategy, formulary evidence, and portfolio-level prioritization. Its engagement patterns favor technical continuity through modeling and write-up phases, which reduces rework when stakeholders request changes to assumptions, endpoints, or comparator structures. The work often extends beyond deterministic outputs into uncertainty handling that supports scenario analysis for decision meetings.

A tradeoff appears when stakeholders expect an off-the-shelf modeling system or rapid self-service configuration, since Milliman’s value concentrates in analyst-run studies rather than productized automation. Milliman fits best when internal teams need an external modeling partner to translate clinical and utilization evidence into decision-ready outputs for governance and health technology assessment committees.

Pros
  • +Analyst ownership across modeling, assumptions, and decision narrative
  • +Strong support for comparator, horizon, and perspective changes
  • +Clear traceability from evidence inputs to model outputs
  • +Consistent handling of uncertainty for scenario-based discussions
Cons
  • –Limited self-service experience compared with workflow tools
  • –Requires disciplined scoping to avoid repeated assumption revisions
  • –Turnaround depends on data availability and stakeholder feedback cadence
  • –Advanced model customization can increase project complexity
Use scenarios
  • Payer medical policy teams

    Budget impact for new therapy

    Governance-ready reimbursement recommendation

  • HTA and reimbursement analysts

    Cost-effectiveness dossier support

    Defensible ICER estimates

Show 2 more scenarios
  • Life sciences market access

    Scenario analysis for launch planning

    Improved decision alignment

    Assumption and endpoint variants support internal tradeoffs for market access strategy.

  • Clinical evidence and HEOR leads

    Evidence-to-model integration

    Faster stakeholder review

    Model inputs are connected to clinical endpoints and resource utilization assumptions.

Best for: Fits when payer and sponsor teams need rigorous, consultant-built economic models with decision-ready documentation.

#2

L.E.K. Consulting

enterprise_vendor

Strategy consulting firm with life sciences practice including health economics services.

8.8/10
Overall
Features8.8/10
Ease of Use8.7/10
Value8.9/10
Standout feature

End-to-end economic modeling and evidence-to-outputs traceability that supports repeatable scenario reruns for policy decisions.

Health economics work at L.E.K. typically centers on building and populating economic models that connect treatment effects, healthcare resource utilization, and cost inputs into decision-ready results. The engagement style fits teams that need controlled assumptions, documented sensitivity logic, and results that can be defended in cross-functional review cycles. Automation is most useful when internal users require consistent reruns for scenario analysis and policy variants rather than one-off model builds. Integration depth tends to be strongest when stakeholders align on model specifications early and provide the evidence inputs needed for build and QA cycles.

A key tradeoff is that deep economic-model custom work benefits from early requirements clarity, because model structure choices and evidence mapping drive downstream build effort. L.E.K. works best when timelines require disciplined iteration on discounting, perspective, time horizon, and sensitivity parameters, such as probabilistic sensitivity analysis and scenario analysis for HTA-style submissions. For usage situations where internal teams already have a preferred modeling template, L.E.K. can integrate more smoothly by aligning to the existing structure and reporting conventions. For teams seeking only lightweight scoping or presentation, the consulting approach can feel heavier than model-only support.

Governance and auditability tend to be handled through structured workplans, explicit assumption logs, and controlled output formats that support internal and external review. This fits payer-facing and reimbursement workflows where decision makers need traceable rationale from evidence to incremental outcomes. It also fits multi-stakeholder programs where clinical, economic, and policy teams must converge on the same parameter definitions.

Pros
  • +Decision-grade economic outputs linked to explicit assumptions
  • +Scenario analysis support for payer policy and reimbursement use
  • +Structured sensitivity work suitable for HTA-style scrutiny
  • +Clear traceability from evidence inputs to incremental results
Cons
  • –Requires early alignment on model structure and evidence mapping
  • –Heavier consulting footprint than model-only support
  • –API and automation options are not a self-serve modeling product
  • –Rerun throughput depends on how inputs and drivers are packaged
Use scenarios
  • Payer health economics teams

    HTA-style cost-effectiveness scenario modeling

    Defensible reimbursement narrative

  • Market access strategy teams

    Policy variant and sensitivity reruns

    Consistent decision outputs

Show 2 more scenarios
  • Biopharma HEOR leads

    Evidence synthesis to economic model inputs

    Faster model readiness

    Maps evidence findings into model parameters with controlled assumptions and documented sensitivities.

  • Clinical trial economics leads

    Resource use and cost parameter translation

    Aligned economic assumptions

    Converts healthcare utilization evidence into cost inputs to produce decision-grade economic results.

Best for: Fits when reimbursement and payer stakeholders need defensible economic modeling, sensitivity logic, and traceable assumptions.

#3

Simon-Kucher & Partners

enterprise_vendor

Global strategy consulting firm with pharmaceutical pricing and health economics practice.

8.6/10
Overall
Features8.6/10
Ease of Use8.6/10
Value8.6/10
Standout feature

Decision narrative integration that connects model assumptions and scenario results to commercial and HTA-facing positions.

Simon-Kucher & Partners supports health economics studies that connect clinical evidence to economic decision criteria, including model-based assessments and comparative scenarios. Delivery commonly targets decision artifacts such as cost drivers, assumptions documentation, and justification packages for stakeholders who need to align technical results with commercial positions.

A tradeoff appears when internal teams need heavy hands-on model building guidance, because engagement leadership typically focuses on deliverables rather than extensive knowledge transfer to every model component. Simon-Kucher & Partners fits best when a payer or pharma team needs an economics partner to manage end-to-end reasoning from evidence inputs to decision narrative, then stress assumptions for distinct negotiating or reimbursement scenarios.

Pros
  • +Strong linkage between economic outputs and commercial decision framing
  • +Clear assumption documentation for stakeholder review and alignment
  • +Scenario work that supports pricing and reimbursement argumentation
  • +Experience running economic models suitable for HTA-style questions
Cons
  • –Less hands-on model coaching for teams building from scratch
  • –Model scope can widen when evidence gaps require extra synthesis
  • –Governance artifacts may be time-consuming for fast-moving teams
  • –Interaction bandwidth can be limiting for highly iterative cycles
Use scenarios
  • Pricing and market access teams

    Prepare reimbursement negotiation economic evidence

    Aligned decision package for stakeholders

  • HTA strategy leads

    Respond to assessment questions

    Clearer internal HTA response

Show 2 more scenarios
  • RWE and evidence teams

    Quantify economic model parameters

    Model inputs grounded in evidence

    Use evidence synthesis to populate cost and utilization inputs for comparative analyses.

  • Portfolio decision groups

    Compare strategic investment options

    Comparable options for selection

    Support comparative evaluations using consistent assumptions across scenarios for decision makers.

Best for: Fits when teams need decision-ready health economics tied to pricing and reimbursement negotiation.

#4

IQVIA

enterprise_vendor

Global healthcare data, analytics, and research organization with health economics services.

8.3/10
Overall
Features8.3/10
Ease of Use8.3/10
Value8.3/10
Standout feature

A structured model-assembly workflow that traces evidence inputs into parameter definitions and reporting deliverables for submission-style review.

IQVIA delivers health economics services that connect evidence synthesis, model building, and decision-ready outputs for payer and provider stakeholders. Teams commonly support economic model development across decision tree, Markov, and partitioned survival structures, with transparent assumptions for time horizon, perspective, and discounting.

Pros
  • +End-to-end workflow from evidence inputs to calibrated economic model outputs
  • +Strong support for multiple model structures used in reimbursement submissions
  • +Documented assumption management for time horizon, perspective, and discounting
  • +Data-to-parameter mapping from claims or EHR into resource and outcomes inputs
Cons
  • –Governance-heavy delivery can slow timelines for narrow-scope requests
  • –Complex modeling work increases dependency on timely client data provisioning
  • –Less suitable for teams needing fully self-serve model authoring
  • –Requires clear alignment on endpoints and utility inputs early in planning

Best for: Fits when payer-facing economic models need rigorous evidence linkage and controlled, reviewable assumptions.

#5

ICON plc

enterprise_vendor

Clinical research organization providing health economics and outcomes research services.

8.2/10
Overall
Features8.2/10
Ease of Use8.2/10
Value8.2/10
Standout feature

Project-managed economic model builds with documented assumption traceability across scenarios and sensitivity workstreams.

ICON plc produces health economics and outcomes research deliverables, including full economic model builds and analyses for health technology assessment and payer decisions. Teams support decision-ready outputs that connect clinical evidence inputs to cost and utility assumptions, with documented model logic used across scenario and sensitivity work.

Pros
  • +End-to-end ownership of economic modeling from evidence inputs to submission outputs
  • +Clear traceability from assumptions to drivers in scenario and sensitivity results
  • +Experience translating clinical endpoints into utility and cost parameters for decision use
  • +Structured project management for coordinated model, reporting, and response cycles
Cons
  • –Collaboration depends on timely provision of evidence packages and cost frameworks
  • –Less suited for teams needing self-serve model tooling and analyst workflows
  • –Model customization depth may increase iteration cycles during scoping changes
  • –Output polish is strong for submissions but limited for rapid internal experimentation

Best for: Fits when sponsors need managed health economics modeling and submission-grade decision outputs.

#6

Costello Medical

specialist

Health economics and medical communications consultancy serving global life sciences clients.

7.7/10
Overall
Features7.7/10
Ease of Use7.7/10
Value7.7/10
Standout feature

Senior-led decision modeling that ties evidence inputs to transparent assumptions and stakeholder-ready scenario interpretation.

Costello Medical is a health economics and health technology assessment consultancy built for teams that need defensible economic modeling for submissions and payer negotiations. Core work covers evidence synthesis to populate economic models, alongside model development for typical decision-analytic structures and uncertainty work that supports stakeholder decision-making.

Pros
  • +Consultancy-led modeling with strong assumption traceability for submission scrutiny
  • +Clear linkage between evidence inputs and model parameters for governance-ready reviews
  • +Experienced handling of uncertainty work for payer-focused decision narratives
  • +Practical scenario design aligned to access and policy questions
Cons
  • –Delivery depends on consultancy resourcing rather than self-serve workflows
  • –Heavier governance documentation can increase internal review time for new teams
  • –Model handover format may require analyst support to re-run and audit fully

Best for: Fits when payer-facing economic models must align evidence, assumptions, and uncertainty for HTA timelines.

#7

Charles River Associates

specialist

Economics and finance consulting firm with healthcare and life sciences practice.

7.5/10
Overall
Features7.5/10
Ease of Use7.5/10
Value7.5/10
Standout feature

Policy-focused modeling documentation that ties evidence inputs to economic assumptions and scenario outcomes for technical scrutiny.

Charles River Associates delivers health economics work rooted in applied decision modeling and policy-grade economic analysis, often executed for complex payer, regulator, and litigation timelines. Core capabilities include comparative economic evaluations, budget impact analysis, and evidence-informed model building that supports reimbursement and HTA-style decision framing.

Pros
  • +Strong capability for decision-analytic modeling across multi-stage pathways
  • +Costing assumptions are built to withstand regulator and payer scrutiny
  • +Transparent scenario logic supports line-by-line technical review
  • +Experienced at evidence synthesis inputs for model-based economic outcomes
Cons
  • –Collaboration requires tight technical scoping to avoid rework
  • –Automation and API surface are limited since delivery is largely services-based
  • –Turnaround depends on model scope and evidence procurement complexity
  • –Governance controls are more consultative than software-native

Best for: Fits when policy-grade economic models need strong documentation and defensible scenario framing for reimbursement or regulatory review.

#8

Putnam Associates

specialist

Strategy consulting firm serving life sciences with health economics and value evidence services.

7.0/10
Overall
Features7.0/10
Ease of Use7.0/10
Value7.0/10
Standout feature

Engagement-led economic modeling that prioritizes dossier-ready transparency of assumptions, scenarios, and results.

Putnam Associates delivers health economics services built around economic modeling, value evidence, and decision support for payers and life sciences. Teams commonly use its modeling work for payer-facing health technology assessment and comparative effectiveness decisions that need transparent assumptions and repeatable calculations.

Pros
  • +End-to-end economic model development for stakeholder-ready deliverables
  • +Consistent handling of model assumptions and scenario structures across engagements
  • +Experience supporting payer and HTA-style economic decision contexts
  • +Clear support for decision-oriented reporting needs and impact narratives
Cons
  • –Collaboration overhead can rise when inputs require heavy data cleaning
  • –Model refinement cycles may take longer when endpoints or estimands shift late
  • –Tooling depth is limited for users expecting self-serve modeling automation
  • –Governance controls depend on engagement process rather than productized workflows

Best for: Fits when stakeholder-facing health economic models must be built, maintained, and documented end to end.

#9

RTI Health Solutions

specialist

Health economics and outcomes research consulting firm serving pharmaceutical and medical device clients.

6.8/10
Overall
Features6.8/10
Ease of Use6.8/10
Value6.8/10
Standout feature

Decision-focused economic modeling deliverables that translate evidence to scenario-specific incremental results.

RTI Health Solutions produces health economics and outcomes research deliverables that connect clinical evidence to payer and policy decisions, with clear emphasis on model-driven decision support. The core work covers cost-effectiveness and related economic modeling, value frameworks, and evidence synthesis outputs used in health technology assessment and comparative effectiveness contexts.

Pros
  • +Economic modeling work products suited for payer and HTA decision workflows
  • +Strong focus on uncertainty handling for scenario and sensitivity outputs
  • +Delivery includes stakeholder-ready tables and documentation for model inputs
  • +Methodology depth supports complex study design and evidence synthesis decisions
Cons
  • –Model build timelines can be sensitive to scoping and data availability
  • –Integration and automation tooling is not positioned as an API-first service
  • –Customization requests can require higher-level oversight from client leads
  • –Outputs remain document-centric rather than interactive for model exploration

Best for: Fits when payers, sponsors, or HTA groups need decision-grade economic modeling with documented assumptions.

#10

Health Advances

specialist

Healthcare strategy consulting firm offering health economics and market access services.

6.7/10
Overall
Features6.7/10
Ease of Use6.7/10
Value6.7/10
Standout feature

Submission-focused model documentation that ties assumptions to scenario outputs for HTA stakeholder review.

Health Advances delivers health economics and health technology assessment work centered on economic modeling, comparative evidence synthesis, and decision-ready outputs for payer and HTA stakeholders. Teams typically use Health Advances when a study requires a full economic model lifecycle from scope and structure through scenario work and documentation.

Pros
  • +Economic model build support for decision-ready HTA submissions
  • +Structured documentation of model assumptions and scenarios
  • +Experience translating clinical endpoints into economic inputs
  • +Clear analyst deliverables for reviewers and internal stakeholders
Cons
  • –Limited evidence of API and automation for internal tooling integration
  • –Governance controls appear engagement-based rather than platform-based
  • –Model transparency depends heavily on analyst documentation quality
  • –Throughput for large multicountry bundles may require parallel workstreams

Best for: Fits when teams need consultant-led economic modeling and HTA-ready documentation for a defined submission scope.

Conclusion

After evaluating 10 health economics, Milliman stands out as our overall top pick — it scored highest across our combined criteria of features, ease of use, and value, which is why it sits at #1 in the rankings above.

Our Top Pick
Milliman

Use the comparison table and detailed reviews above to validate the fit against your own requirements before committing to a tool.

Frequently Asked Questions About Health Economics

Which providers are the best fit for building a decision model from evidence to outputs with tight traceability?
IQVIA and Milliman both emphasize traceability between evidence inputs, parameter definitions, and decision-ready outputs. Charles River Associates also supports policy-grade economic modeling, but it typically centers more on defensible scenario framing for reimbursement and regulator-facing review cycles than on an end-to-end internal model lifecycle.
How do service delivery models differ between consultancy-led work and interactive or tooling-based workflows?
Health Advances and Costello Medical typically deliver consultancy-built artifacts like model files, documentation, and traceable assumption logs, which suits teams that govern model changes through review meetings. ICON plc and IQVIA often run structured project workflows with model QA checkpoints and audit-traceable artifacts, which fits organizations that want controlled throughput across multiple model builds.
What breaks if the client needs frequent model reruns driven by updated evidence, assumptions, or dossier edits?
Putnam Associates supports end-to-end economic model development and maintains dossier-ready transparency across scenarios, which helps when reruns are recurring. L.E.K. Consulting focuses on transparent drivers and repeatable scenario logic, but rerun cadence can become a governance problem if the internal team cannot maintain consistent inputs and parameter mappings for each cycle.
When does a budget impact analysis need different expertise than a cost-effectiveness analysis?
RTI Health Solutions and Milliman commonly translate incremental outputs into stakeholder-specific decision materials, including budget impact workstreams that align to time horizons and payer perspectives. Charles River Associates typically leans toward policy-grade economic framing, where budget impact assumptions must be justified for adoption and uptake rather than treated as a mechanical extension of cost-effectiveness.
How should teams prepare claims data or electronic health record data so model inputs stay auditable?
IQVIA is structured for large-scale data-to-model workflows that populate healthcare resource utilization and effectiveness parameters from claims, electronic health record data, and real-world evidence inputs. ICON plc and L.E.K. Consulting also connect evidence inputs to economic assumptions, but they require clearer evidence packages and cost framework alignment earlier in the build to prevent late-stage parameter rewrites.
Which providers handle evidence synthesis tightly enough to populate the economic model without manual translation layers?
Costello Medical focuses on evidence synthesis paired with model development, which reduces gaps between literature inputs and model parameterization. RTI Health Solutions also supports decision-grade economic modeling with documented assumptions, but the strongest fit occurs when the evidence package is structured for model extraction rather than delivered as narrative summaries.
What security and governance controls should buyers expect around model change control and audit trails?
IQVIA and Milliman emphasize documented model change control and reviewable artifacts that keep assumption updates explainable across internal committees. Charles River Associates often concentrates on defensible documentation and scenario logic for technical scrutiny, so audit trail depth depends on whether the client has a formal governance workflow for model versioning.
How do data migration and model format handoffs affect onboarding timelines for new vendors?
ICON plc and IQVIA typically compress onboarding when the client can provide reference cost frameworks and evidence packages in usable formats for parameter mapping. Health Advances and Putnam Associates can accept structured dossiers and deliver defined submission-scoped outputs, but onboarding slows when internal teams need repeated schema or data-model alignment between existing spreadsheets and deliverable model templates.
Which providers best support scenario logic that maps cleanly to stakeholder governance and documentation expectations?
L.E.K. Consulting and Charles River Associates both focus on transparent drivers and defensible scenario framing, which makes governance review more traceable. Simon-Kucher & Partners also ties economic model assumptions and scenario results to stakeholder narratives, but scenario logic is most effective when the organization wants commercial and reimbursement positions to be consistent with the modeled assumptions.
When should a project include probabilistic sensitivity work rather than relying only on deterministic sensitivity runs?
RTI Health Solutions and IQVIA support uncertainty work designed to shape incremental outcomes and decision thresholds, which fits when parameter uncertainty materially changes decision direction. Costello Medical can run uncertainty analyses suited to stakeholder needs, but buyers should confirm that the workplan includes enough parameter distributions and evidence linkages to avoid over-reliance on one-way deterministic toggles.

Tools reviewed

Primary sources checked during evaluation.

Referenced in the comparison table and product reviews above.

How to Choose the Right Health Economics

We see real differences in how well a health economics tool ties study inputs to outcomes and how transparently it shows results across assumptions. Pick based on evidence traceability and scenario support, not just a polished interface.

Evidence traceability for inputs

Why it matters

Evidence traceability for inputs matters when health economics results need to be defended in reviews and audits. If users can’t trace where parameters come from, findings become hard to replicate or explain.

How to check

In a demo, load an example project and click through a parameter to see its source, date, and citation text. Ask whether the tool stores that link inside the project output so you can export a traceable report.

Assumption and scenario controls

Why it matters

Assumption and scenario controls determine whether you can test alternative interpretations without rebuilding work. Health economics teams often need to compare outcomes under the same structure but different assumptions.

How to check

Set two different assumptions (for example, a key effectiveness value or cost input) and confirm you can switch between them without losing prior results. Check whether scenarios keep separate outputs you can label and export.

Uncertainty workflow for sensitivity

Why it matters

An uncertainty workflow for sensitivity matters because health economics conclusions depend on robustness, not single-point estimates. Tools should let analysts show what changes and why.

How to check

Run a sensitivity exercise using the built-in example or upload a small dataset. Confirm you can review which inputs drive variation and export the uncertainty outputs alongside the main results.

Reproducible outputs from saved settings

Why it matters

Reproducible outputs from saved settings matter for peer review and internal sign-off. If re-running produces different numbers, you can’t credibly audit changes.

How to check

Export results, then reload the project and rerun the same analysis using identical settings. Compare key output figures for exact matches (or documentable differences if the tool explains why).

Transparent reporting of assumptions

Why it matters

Transparent reporting of assumptions helps stakeholders understand what the model assumed and what it did not. In health economics, unclear reporting undermines decision usefulness.

How to check

Generate the standard report for an example study and inspect whether it lists assumptions, sources, and outputs in a consistent structure. Ask if you can edit report sections and ensure exported files retain those details.

Red flags

  • Inputs can be changed but sources aren’t stored in the project output
  • Scenario changes overwrite results instead of keeping labeled alternatives
  • Rerunning the same saved settings produces different outputs without explanation

Fit by situation

  • If we need audit-ready documentation for parameters and their origins, prioritize evidence traceability for inputs.
  • If we expect stakeholders to challenge assumptions during review, prioritize assumption and scenario controls.
  • If we must show robustness rather than point estimates, prioritize uncertainty workflow for sensitivity.
Commissioned Research

Funding and competing interests

This study was co-funded by several of the vendors assessed in it. No single vendor funded it. Funders could propose the market studied.

They had no role in selecting vendors, setting or weighting criteria, analysing data or drawing conclusions, and they received the same factual-accuracy check as every other vendor assessed.

Market definition, inclusion rules and criteria weights were fixed by an editor before research began and did not change afterwards. Editorial process →

Keep exploring

FOR SOFTWARE VENDORS

Not on this list? Let’s fix that.

Our best-of pages are how many teams discover and compare tools in this space. If you think your product belongs in this lineup, we’d like to hear from you—we’ll walk you through fit and what an editorial entry looks like.

Apply for a Listing

WHAT THIS INCLUDES

  • Where buyers compare

    Readers come to these pages to shortlist software—your product shows up in that moment, not in a random sidebar.

  • Editorial write-up

    We describe your product in our own words and check the facts before anything goes live.

  • On-page brand presence

    You appear in the roundup the same way as other tools we cover: name, positioning, and a clear next step for readers who want to learn more.

  • Kept up to date

    We refresh lists on a regular rhythm so the category page stays useful as products and pricing change.